Lansing-based BioPort Corp. awarded anthrax vaccine contract
By KEN THOMAS
The Associated Press
WASHINGTON (AP) — BioPort Corp. will receive $120 million to produce 5 million more doses of anthrax vaccine to bolster the government's stockpile of antidotes against bioweapons, the Department of Health and Human Services said Friday.
The Lansing, Mich.-based company is the nation's only licensed manufacturer of the anthrax vaccine. BioPort recently completed delivery of 5 million doses of anthrax vaccine to the federal stockpile that was funded by a $122.7 million contract announced in May 2005.
"We are committed to protecting the nation from the consequences of an anthrax attack," said Stewart Simonson, HHS's assistant secretary for public health emergency preparedness. HHS said it would modify the contract announced last year to purchase the additional doses of Anthrax Vaccine Adsorbed.
The contract was awarded under Project BioShield, which was signed into law by President Bush in July 2004 with the promise of spending $5.6 billion to develop remedies against possible bioweapons.
The Associated Press
WASHINGTON (AP) — BioPort Corp. will receive $120 million to produce 5 million more doses of anthrax vaccine to bolster the government's stockpile of antidotes against bioweapons, the Department of Health and Human Services said Friday.
The Lansing, Mich.-based company is the nation's only licensed manufacturer of the anthrax vaccine. BioPort recently completed delivery of 5 million doses of anthrax vaccine to the federal stockpile that was funded by a $122.7 million contract announced in May 2005.
"We are committed to protecting the nation from the consequences of an anthrax attack," said Stewart Simonson, HHS's assistant secretary for public health emergency preparedness. HHS said it would modify the contract announced last year to purchase the additional doses of Anthrax Vaccine Adsorbed.
The contract was awarded under Project BioShield, which was signed into law by President Bush in July 2004 with the promise of spending $5.6 billion to develop remedies against possible bioweapons.
